Skip to main content
Premium Trial:

Request an Annual Quote

Christopher Moreau, Jim Charlton

Premium
Christopher Moreau was appointed president and CEO of Miraculins this week, replacing Jim Charlton who stepped down. Charlton remains a member of Miraculin’s board and will continue to provide guidance to the company, it said in a statement.
 
Moreau had served as vice president of business development since joining the company in March 2006. Before that he was president of Advansis Capital, a privately held Canadian financial services firm. The company did not disclose Moreau’s new salary, but said that it has granted him 130,000 stock options at an excise price of CA$.53 per share.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.